Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
S Zhou, L Xie, C Zhou, L Wang, J Chen… - Clinical and …, 2023 - Wiley Online Library
Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
Efficacy of keverprazan for duodenal ulcer: a phase II randomized, double‐blind, parallel‐controlled trial
N Tan, X Liu, C Liu, S Li, H Chen, X Li… - Journal of …, 2022 - Wiley Online Library
Abstract Background and Aim Considering the limitation of varying acid suppression of
proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect …
proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose–effect …
Efficacy and Safety of Keverprazan Compared With Lansoprazole in the Treatment of Duodenal Ulcer: A Phase III, Randomized, Double-Blind, Multicenter Trial
X Miao, A Liao, C Liu, H Wu, H Chen, F Li… - Clinical and …, 2023 - journals.lww.com
METHODS: In this phase III, double-blind, multicenter study, 360 Chinese patients with
endoscopically confirmed active DU were randomized 1: 1 to take either keverprazan (20 …
endoscopically confirmed active DU were randomized 1: 1 to take either keverprazan (20 …